Lineage Cell Therapeutics
LCTX
57 hedge funds and large institutions have $70.1M invested in Lineage Cell Therapeutics in 2014 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 19 increasing their positions, 19 reducing their positions, and 10 closing their positions.
6% more capital invested
Capital invested by funds: $66.3M → $70.1M (+$3.84M)
0.23% more ownership
Funds ownership: 37.31% → 37.54% (+0.23%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 19
8% less funds holding
Funds holding: 62 → 57 (-5)
50% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 10
90% less call options, than puts
Call options by funds: $59K | Put options by funds: $575K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$1.1M |
| 2 |
WSCM
Wellington Shields Capital Management
New York
|
+$377K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$345K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$298K |
| 5 |
BIT
BlackRock Institutional Trust
San Francisco,
California
|
+$289K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
-$385K |
| 2 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$358K |
| 3 |
Morgan Stanley
New York
|
-$212K |
| 4 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
-$141K |
| 5 |
Jane Street
New York
|
-$69K |
LCTX Hedge Fund Activity: Q3 2014 in Review
57 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2014, worth a combined $70.1M — up 5.8% from $66.3M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of LCTX and 5 opened new positions — a net loss of 5 holders — while 19 trimmed existing stakes and 19 added.
The largest buyer was Broadwood Capital, adding an estimated $1.1M. The largest seller was Northeast Financial Consultants, exiting entirely with an estimated $385K sold.
- 57 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2014, down from 62 in Q2 2014.
- Funds reported $70.1M of Lineage Cell Therapeutics stock for Q3 2014, up 5.8% quarter-over-quarter.
- 5 funds opened new Lineage Cell Therapeutics positions in Q3 2014 and 10 closed out, a net change of -5 holders.
- The largest Lineage Cell Therapeutics buyer in Q3 2014 was Broadwood Capital, an estimated $1.1M added.
- The largest Lineage Cell Therapeutics seller in Q3 2014 was Northeast Financial Consultants, an estimated $385K sold.
Based on aggregated 13F filings for Q3 2014.